Stock comparison
LeMaitre Vascular
Viatris
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
VTRS
Viatris
Market cap
$19.39B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | VTRS | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 31F | LMAT |
| Benjamin Graham | 89A | 27F | LMAT |
| Philip Fisher | 81C | 18F | LMAT |
| Peter Lynch | 67B | 7F | LMAT |
| Joel Greenblatt | 56D | 0F | LMAT |
| Charlie Munger | 68D | 26F | LMAT |
| Terry Smith | 69D | 17F | LMAT |
Side-by-side metrics
| Metric | LMAT | VTRS |
|---|---|---|
| Market cap | $2.23B | $19.39B |
| P/E (TTM) | 37.1x | - |
| EV/EBIT | 36.6x | - |
| ROIC (TTM) | 9.43% | 0.16% |
| Gross margin | 72.39% | 34.4% |
| Net margin | 24.35% | -2.04% |
| Revenue CAGR 5y | 12.75% | -5.44% |
| EPS CAGR 5y | 19.04% | -69.69% |
| Debt / Equity | 0.5x | 1.0x |
| Dividend yield | 0.84% | 2.8% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- Revenue CAGR 5y12.75%vs -5.44%+143%
- EPS CAGR 5y19.04%vs -69.69%+127%
- Net margin24.35%vs -2.04%+108%
- ROIC (TTM)9.43%vs 0.16%+98%
VTRS leads on
- P/E (TTM)-vs 37.1x+156%
- EV/EBIT-vs 36.6x+133%
- Market cap$19.39Bvs $2.23B+88%
- Dividend yield2.8%vs 0.84%+70%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.